Taro Pharmaceutical Industries Ltd. (TARO) Stock Analysis

Taro Pharmaceutical Industries Ltd. (TARO) Healthcare & Pipeline Overview

Taro Pharmaceutical Industries Ltd. is a science-based pharmaceutical company focused on developing, manufacturing, and marketing specialty and generic products. With a global presence spanning the US, Canada, and Israel, Taro serves diverse therapeutic areas, distributing through established channels and maintaining a moderate beta of 0.56.

What Is the Investment Thesis for TARO?

Taro Pharmaceutical Industries Ltd. presents a mixed investment thesis. The company's established presence in the generic pharmaceutical market, coupled with a diverse product portfolio, provides a stable revenue base, reflected in its $1.62B market cap. A profit margin of 8.6% and gross margin of 48.5% indicate reasonable profitability. However, a P/E ratio of 29.99 suggests the stock may be richly valued compared to peers. Growth catalysts include expansion into new therapeutic areas and geographic markets. Potential risks include increasing competition in the generic drug market and regulatory pressures on pricing. Investors should closely monitor Taro's ability to innovate and maintain its market share in key product categories.

Based on FMP financials and quantitative analysis

TARO Key Highlights

Market capitalization of $1.62B indicates a substantial company size within the specialty and generic pharmaceutical industry.

• P/E ratio of 29.99 suggests a premium valuation compared to the broader market, reflecting investor expectations for future growth.
• Profit margin of 8.6% demonstrates the company's ability to generate profits from its sales, though it could be higher compared to industry leaders.
• Gross margin of 48.5% reflects efficient manufacturing and pricing strategies, contributing to overall profitability.
• Beta of 0.56 indicates lower volatility compared to the market, suggesting a more stable investment profile.

Who Are TARO's Competitors?

TARO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TARO's Key Strengths?

Diverse product portfolio across multiple therapeutic areas.

• Established presence in key markets, including the United States, Canada, and Israel.
• Vertically integrated manufacturing capabilities.
• Strong distribution network.

What Are TARO's Weaknesses?

Reliance on generic pharmaceutical products, which are subject to pricing pressure.

• Limited presence in emerging markets compared to larger competitors.
• Exposure to regulatory risks and compliance requirements.
• Dependence on key suppliers for active pharmaceutical ingredients (APIs).

What Could Drive TARO Stock Higher?

Potential FDA approvals for new generic drug applications (ANDAs) in the pipeline.

• Expansion of distribution network in emerging markets.
• Strategic acquisitions of smaller pharmaceutical companies or product lines.
• Development and launch of new over-the-counter (OTC) products.

What Are the Key Risks for TARO?

Increased competition from other generic pharmaceutical manufacturers.

• Pricing pressure from healthcare payers and pharmacy benefit managers (PBMs).
• Regulatory changes and compliance requirements.
• Product liability claims and litigation.

What Are the Growth Opportunities for TARO?

• Geographic Expansion: Taro has the opportunity to expand its presence in emerging markets, where demand for affordable generic medications is growing rapidly. By establishing distribution networks and partnerships in regions like Asia and Latin America, Taro can tap into new revenue streams and diversify its geographic footprint. The global generics market in emerging economies is projected to reach $250 billion by 2027, offering significant growth potential for Taro.
• Product Pipeline Development: Investing in research and development to expand its product pipeline is crucial for Taro's long-term growth. Focusing on developing generic versions of high-value branded drugs that are losing patent protection can provide significant revenue opportunities. The market for off-patent drugs is estimated at $80 billion annually, presenting a substantial target for Taro's R&D efforts. Timeline: Ongoing.
• Strategic Acquisitions: Taro can pursue strategic acquisitions of smaller pharmaceutical companies or specific product lines to expand its portfolio and market share. Acquiring companies with complementary therapeutic areas or geographic presence can accelerate Taro's growth and enhance its competitive position. The pharmaceutical M&A market is expected to remain active, providing opportunities for Taro to acquire valuable assets. Timeline: Ongoing.
• Dermatology Focus: Taro has a strong presence in the dermatology market, and it can further capitalize on this by developing and marketing innovative dermatological products. The global dermatology market is projected to reach $35 billion by 2028, driven by increasing demand for treatments for skin conditions like acne, eczema, and psoriasis. Taro can leverage its expertise and distribution network to capture a larger share of this growing market. Timeline: Ongoing.
• Over-the-Counter (OTC) Expansion: Expanding its portfolio of over-the-counter (OTC) products can provide Taro with a stable revenue stream and reduce its reliance on prescription drugs. The global OTC market is projected to reach $200 billion by 2027, driven by increasing self-medication trends and the availability of more OTC medications. Taro can develop and market OTC versions of its existing prescription drugs or acquire established OTC brands to expand its presence in this market. Timeline: Ongoing.

What Are TARO's Competitive Advantages?

• Established presence in the generic pharmaceutical market.
• Diverse product portfolio across multiple therapeutic categories.
• Vertically integrated manufacturing capabilities.
• Strong distribution network in key markets.

What Does TARO Do?

Founded in 1950 and headquartered in Haifa, Israel, Taro Pharmaceutical Industries Ltd. has evolved into a prominent player in the specialty and generic pharmaceutical market. The company develops, manufactures, and markets a wide array of prescription and over-the-counter products, along with active pharmaceutical ingredients. Taro's portfolio spans multiple therapeutic categories, including dermatology, cardiology, neurology, and pediatrics. Its products are available in various dosage forms, such as capsules, creams, tablets, and solutions. Taro distributes its products directly to wholesalers, retail drug store chains, food chains, hospitals, mass merchandisers, and other direct purchasers and customers, as well as healthcare institutions and private pharmacies. Geographically, Taro has a significant presence in the United States, Canada, and Israel, with growing international operations. As a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd., Taro benefits from a stable ownership structure. The company's focus on science-based innovation and efficient manufacturing processes has enabled it to maintain a competitive edge in the generic pharmaceutical landscape. Taro's commitment to quality and regulatory compliance underpins its reputation as a reliable supplier of essential medicines.

What Products and Services Does TARO Offer?

• Develops and manufactures prescription pharmaceutical products.
• Develops and manufactures over-the-counter pharmaceutical products.
• Markets prescription and over-the-counter pharmaceutical products.
• Develops and manufactures active pharmaceutical ingredients (APIs).
• Offers products for various therapeutic categories, including dermatology, cardiology, and neurology.
• Provides products in various dosage forms, such as capsules, creams, and tablets.
• Distributes products directly to wholesalers, retailers, and healthcare institutions.

How Does TARO Make Money?

• Develops and manufactures generic and specialty pharmaceutical products.
• Sells products directly to wholesalers, retail chains, and healthcare providers.
• Generates revenue through product sales in the United States, Canada, Israel, and internationally.

What Industry Does TARO Operate In?

Taro Pharmaceutical Industries Ltd. operates within the competitive generic pharmaceutical industry. This sector is characterized by intense pricing pressure, regulatory scrutiny, and the need for continuous innovation. The global generic drug market is projected to reach $478 billion by 2028, driven by increasing demand for affordable medicines. Taro competes with other generic manufacturers, including Amneal Pharmaceuticals (AMAM), Assertio Holdings (ASTH), and others, all vying for market share. Success in this industry requires efficient manufacturing, strong regulatory compliance, and a robust product pipeline.

Who Are TARO's Key Customers?

• Wholesalers
• Retail drug store chains
• Hospitals
• Mass merchandisers
• Healthcare institutions

Company Profile

Taro Pharmaceutical Industries Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Haifa, IL. The company is led by CEO Uday V. Baldota. TARO has traded publicly since 1982.

Taro Pharmaceutical Industries Ltd. (TARO) Valuation Context

Valued at $1.62B, TARO is classified as a small-cap stock.

Return on equity for Taro Pharmaceutical Industries Ltd. stands at 3.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 2.5%, showing how much profit it generates from its asset base. TARO trades at a trailing price-to-earnings ratio of 29.99, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.3%, the inverse of the P/E and a quick read on earnings relative to price.

Taro Pharmaceutical Industries Ltd.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.49 places it in the safe zone, indicating low near-term bankruptcy risk.

TARO Financials

TARO Latest News

No recent news available for TARO.

TARO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources